Examples of using Tipranavir in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Tipranavir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
It is unknown whether the combination of tipranavir with ritonavir might cause a larger increase in fluticasone exposure.
The concurrent administration of tipranavir and low dose ritonavir may result in increased risk of cardiovascular adverse events associated with salmeterol,
Tipranavir, co-administered with low dose ritonavir,
Preclinical studies performed with tipranavir showed no adverse effect on fertility see section 5.3.
nevirapine, tipranavir/ritonavir, or rifampicin.
Therefore, tipranavir with ritonavir should not be used in treatment-naïve patients see section 4.2.
nevirapine, tipranavir/ritonavir, or rifampicin.
An increase in gastric pH that may result from H2-receptor antagonist therapy is not expected to have an impact on tipranavir plasma concentrations.
Doses of ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of the combination.
Based on theoretical considerations, bosentan concentrations may increase upon co-administration with tipranavir and low dose ritonavir.
agents that induce CYP3A and/or P-gp may decrease tipranavir concentrations and reduce its therapeutic effect see list and details of considered agents, below.
Patients using clarithromycin at doses higher than 500 mg twice daily should be carefully monitored for signs of toxicity of clarithromycin and tipranavir.
The mechanisms and potential mechanisms contributing to the interaction profile of tipranavir are described see section 4.5.
saquinavir, tipranavir.
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase amiodarone,
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir,
A correlation between the tipranavir mutation score and response to tipranavir with ritonavir therapy at week 48 has been established.
At 48 weeks these rates were 25.2% of patients in the tipranavir with ritonavir arm
When co-administered, tipranavir and cobicistat exposures are markedly lower compared to that of tipranavir when boosted with low dose ritonavir.